SARS-CoV-2: ACE inhibitors, disastrous or desirable?

Authors

DOI:

https://doi.org/10.3126/jbs.v7i1.29852

Keywords:

ACE 2 receptors, ACE inhibitors, angiotensin-converting enzyme inhibitors, COVID-19, SARS-CoV-2

Abstract

Background: The world has a current total of 6,663,304 confirmed cases of COVID-19 with a death count of 392,802 deaths according to the WHO (6 June 2020). Various risk factors for the acquisition and subsequent development of deadly complications due to the virus have been established. One such risk factor is the presence of cardiovascular disease, particularly hypertension as a comorbidity. It must be noted that JNC 8 advise the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers as first line drugs for the management of hypertension. ARDS is caused by the activation of angiotensin I, angiotensin II and AT1 receptor pathway, however stimulation of Mas receptor, MRGPR receptors, AT2 receptor and the ACE-2-angiotensin (1-7), pathways is found to be defensive.  Mas receptor exerts an inhibitory effect on inflammation and cellular growth and vascular mechanisms.  This research aims to examine the relationship between ACE inhibitors and the risk of COVID-19 infections with the goal of determining whether this relationship is spurious in association or whether it is causative in nature? More specifically, in this research article we will determine whether the SARS-CoV-2 virus has an affinity for ACE 2 receptors in humans. Furthermore, it will be determined whether ACE inhibitors would inhibit or facilitate an imminent COVID-19 infection in individuals as well as to  determine whether patients currently using ACE inhibitors should continue or discontinue the drug therapy in order to minimize their susceptibility to acquiring COVID-19, and whether patients should start ACE inhibitor therapy if required during this pandemic.

Conclusion: It is evident that ACE 2 receptors are the portal of entry for SARS-CoV-2. It is recommended that the use of RAAS inhibitors, viz ACE inhibitors and angiotensin receptor blockers is not stopped or decreased despite the ongoing pandemic as the results thereof may lead to the worsening of the patient’s comorbidity and may hasten death.

Downloads

Download data is not yet available.
Abstract
613
PDF
394

Author Biographies

Alexandra Leclézio, Sir Seewoosagur Ramgoolam Medical College, Mauritius

Final Part II medical student

Jared Robinson, Sir Seewoosagur Ramgoolam Medical College, Mauritius

2nd Professional medical student

Indrajit Banerjee, Sir Seewoosagur Ramgoolam Medical College, Mauritius

Associate Professor, Department of Pharmacology

Downloads

Published

2020-07-03

How to Cite

Leclézio, A., Robinson, J., & Banerjee, I. (2020). SARS-CoV-2: ACE inhibitors, disastrous or desirable?. Journal of Biomedical Sciences, 7(1), 40–46. https://doi.org/10.3126/jbs.v7i1.29852

Issue

Section

Reviews